154 related articles for article (PubMed ID: 24936706)
1. Reduction of the nitro group to amine by hydroiodic acid to synthesize o-aminophenol derivatives as putative degradative markers of neuromelanin.
Wakamatsu K; Tanaka H; Tabuchi K; Ojika M; Zucca FA; Zecca L; Ito S
Molecules; 2014 Jun; 19(6):8039-50. PubMed ID: 24936706
[TBL] [Abstract][Full Text] [Related]
2. Norepinephrine and its metabolites are involved in the synthesis of neuromelanin derived from the locus coeruleus.
Wakamatsu K; Tabuchi K; Ojika M; Zucca FA; Zecca L; Ito S
J Neurochem; 2015 Nov; 135(4):768-76. PubMed ID: 26156066
[TBL] [Abstract][Full Text] [Related]
3. The Metabolic Fate of ortho-Quinones Derived from Catecholamine Metabolites.
Ito S; Yamanaka Y; Ojika M; Wakamatsu K
Int J Mol Sci; 2016 Jan; 17(2):. PubMed ID: 26828480
[TBL] [Abstract][Full Text] [Related]
4. The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's disease.
Nagatsu T; Nakashima A; Watanabe H; Ito S; Wakamatsu K; Zucca FA; Zecca L; Youdim M; Wulf M; Riederer P; Dijkstra JM
J Neural Transm (Vienna); 2023 May; 130(5):611-625. PubMed ID: 36939908
[TBL] [Abstract][Full Text] [Related]
5. The structure of neuromelanin as studied by chemical degradative methods.
Wakamatsu K; Fujikawa K; Zucca FA; Zecca L; Ito S
J Neurochem; 2003 Aug; 86(4):1015-23. PubMed ID: 12887698
[TBL] [Abstract][Full Text] [Related]
6. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability.
Zucca FA; Bellei C; Giannelli S; Terreni MR; Gallorini M; Rizzio E; Pezzoli G; Albertini A; Zecca L
J Neural Transm (Vienna); 2006 Jun; 113(6):757-67. PubMed ID: 16755380
[TBL] [Abstract][Full Text] [Related]
7. The neuromelanin of the human substantia nigra.
Carstam R; Brinck C; Hindemith-Augustsson A; Rorsman H; Rosengren E
Biochim Biophys Acta; 1991 Sep; 1097(2):152-60. PubMed ID: 1911888
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous imaging of locus coeruleus and substantia nigra with a quantitative neuromelanin MRI approach.
Chen X; Huddleston DE; Langley J; Ahn S; Barnum CJ; Factor SA; Levey AI; Hu X
Magn Reson Imaging; 2014 Dec; 32(10):1301-6. PubMed ID: 25086330
[TBL] [Abstract][Full Text] [Related]
9. Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins.
Double KL; Zecca L; Costi P; Mauer M; Griesinger C; Ito S; Ben-Shachar D; Bringmann G; Fariello RG; Riederer P; Gerlach M
J Neurochem; 2000 Dec; 75(6):2583-9. PubMed ID: 11080212
[TBL] [Abstract][Full Text] [Related]
10. Riddles in the dark: Decoding the relationship between neuromelanin and neurodegeneration in locus coeruleus neurons.
Iannitelli AF; Weinshenker D
Neurosci Biobehav Rev; 2023 Sep; 152():105287. PubMed ID: 37327835
[TBL] [Abstract][Full Text] [Related]
11. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging.
Zecca L; Stroppolo A; Gatti A; Tampellini D; Toscani M; Gallorini M; Giaveri G; Arosio P; Santambrogio P; Fariello RG; Karatekin E; Kleinman MH; Turro N; Hornykiewicz O; Zucca FA
Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9843-8. PubMed ID: 15210960
[TBL] [Abstract][Full Text] [Related]
12. Differential interactive effects of gliotoxin and MPTP in the substantia nigra and the locus coeruleus in BALB/c mice.
Chang FW; Wang SD; Lu KT; Lee EH
Brain Res Bull; 1993; 31(3-4):253-66. PubMed ID: 7683960
[TBL] [Abstract][Full Text] [Related]
13. Neuromelanin in parkinsonian disorders: an update.
Martin-Bastida A; Pietracupa S; Piccini P
Int J Neurosci; 2017 Dec; 127(12):1116-1123. PubMed ID: 28460588
[TBL] [Abstract][Full Text] [Related]
14. Optimizing neuromelanin contrast in the substantia nigra and locus coeruleus using a magnetization transfer contrast prepared 3D gradient recalled echo sequence.
Liu Y; Li J; He N; Chen Y; Jin Z; Yan F; Haacke EM
Neuroimage; 2020 Sep; 218():116935. PubMed ID: 32413460
[TBL] [Abstract][Full Text] [Related]
15. Association of Locus Coeruleus and Substantia Nigra Pathology With Cognitive and Motor Functions in Patients With Parkinson Disease.
Prasuhn J; Prasuhn M; Fellbrich A; Strautz R; Lemmer F; Dreischmeier S; Kasten M; Münte TF; Hanssen H; Heldmann M; Brüggemann N
Neurology; 2021 Sep; 97(10):e1007-e1016. PubMed ID: 34187859
[TBL] [Abstract][Full Text] [Related]
16. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson's disease.
Farrand AQ; Helke KL; Gregory RA; Gooz M; Hinson VK; Boger HA
Brain Stimul; 2017; 10(6):1045-1054. PubMed ID: 28918943
[TBL] [Abstract][Full Text] [Related]
17. Cysteinyldopamine is not incorporated into neuromelanin.
Wakamatsu K; Ito S; Nagatsu T
Neurosci Lett; 1991 Sep; 131(1):57-60. PubMed ID: 1791980
[TBL] [Abstract][Full Text] [Related]
18. Neuromelanin of the human substantia nigra: an update.
Zucca FA; Basso E; Cupaioli FA; Ferrari E; Sulzer D; Casella L; Zecca L
Neurotox Res; 2014 Jan; 25(1):13-23. PubMed ID: 24155156
[TBL] [Abstract][Full Text] [Related]
19. Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.
Reimão S; Pita Lobo P; Neutel D; Correia Guedes L; Coelho M; Rosa MM; Ferreira J; Abreu D; Gonçalves N; Morgado C; Nunes RG; Campos J; Ferreira JJ
Eur J Neurol; 2015 Mar; 22(3):540-6. PubMed ID: 25534480
[TBL] [Abstract][Full Text] [Related]
20. GC/MS analysis of thermally degraded neuromelanin from the human substantia nigra.
Dzierzega-Lecznar A; Kurkiewicz S; Stepien K; Chodurek E; Wilczok T; Arzberger T; Riederer P; Gerlach M
J Am Soc Mass Spectrom; 2004 Jun; 15(6):920-6. PubMed ID: 15144983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
